HeartFlow FFRCT Analysis

Transforming Coronary Artery Disease Detection


At the intersection of health and technology, HeartFlow leverages advanced technology and applies it to healthcare. With the HeartFlow FFRCT Analysis, HeartFlow is driving towards a new standard of care for the diagnosis and management of coronary artery disease – the number one killer worldwide.

Learn more about our technology in this short video or preview the HeartFlow Analysis by downloading our mobile app (available on iOS in North America and the UK only) or clicking below.

Featured Articles


Applying advanced technologies

Read a perspective from Dr. Robert Safian, Interventional Cardiologist, on how faster turnaround times have allowed his organization to bring HeartFlow to the Emergency Department – deep learning algorithms are helping.

Read Article


Driving value-based healthcare models

In this article, learn how physicians like Dr. Thomas Phiambolis, Director of Cardiac CT Angiography at Lankenau Heart Institute, are transforming cardiovascular care while also reducing costs and improving the patient experience.

Read Article


Pioneering new pathways

Coronary CTs are nothing new, but read on to learn why Dr. Jonathon Leipsic, FRCPC FSCCT, Past President of SCCT, thinks pairing CT with FFRCT is the missing link to help detect coronary artery disease.

Read Article


Contact Us


* Required fields

170,000 Patients Around the World


To date, more than 170,000 patients worldwide have received a HeartFlow Analysis. The momentum is growing with partners in major healthcare systems and local communities bringing HeartFlow to their patients.


See David's Story
A patient and a doctor show HeartFlow app in a tablet
See Dennis' Story
A firefighter and a car in background

Why HeartFlow Matters?


Built on 500+ publications; 400+ patents and decades of R&D and clinical research
Improving outcomes, lowering costs, and supporting a better patient experience1
Leveraging advanced technology including artificial intelligence, deep learning, and cloud computing
Available for use in the US, Canada, Europe and Japan


Contact Us

REFERENCES

  1. Douglas et al. PLATFORM Trial. Eur Heart J. 2015;36(47):3359-67.

37481566 v7